FibroGen's Lead Drug Fails Again, Stock Crashes.

FibroGen's pamrevlumab failed in a Phase III study for idiopathic pulmonary fibrosis, marking the company's third late-stage miss in two months. The drug was not better than placebo at a lung function test and did not delay disease progression. However, it was generally safe and well-tolerated.